Black Diamond Therapeutics Inc.

06/29/2026 | Press release | Distributed by Public on 06/29/2026 14:21

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 26, 2026, Black Diamond Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company's definitive proxy statement (the "Proxy Statement") filed on April 29, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. As of the close of business on April 28, 2026, the record date for the Annual Meeting, the number of shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Annual Meeting was 57,301,774. The number of shares of Common Stock present in person or by remote communication, if applicable, or represented by valid proxy at the Annual Meeting was 44,690,495, thus establishing a quorum for the transaction of business at the Annual Meeting. Shares present virtually during the Annual Meeting were considered shares of Common Stock represented in person at the Annual Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Annual Meeting.

At the Annual Meeting, the Company's stockholders were asked to vote on the following matters, which were described in detail in the Proxy Statement: (i) to elect two Class III director nominees to the Company's Board of Directors (the "Board"), each to serve for a three-year term until the Company's 2029 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified, or until his or her earlier death, resignation or removal ("Proposal No. 1"), (ii) to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal No. 2"), (iii) to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers ("Proposal No. 3"), and (iv) to approve, on a non-binding, advisory basis, the preferred frequency of future non-binding, advisory votes to approve the compensation of the Company's named executive officers ("Proposal 4").

The voting results reported below are final.

Proposal No. 1

Shannon Campbell and Kapil Dhingra were duly elected to the Board as Class III directors. The results of the stockholders' vote with respect to the election of the Class III directors were as follows:

CLASS III DIRECTOR NOMINEE FOR WITHHELD BROKER
NON-
VOTES
Shannon Campbell 19,251,021 17,219,135 8,220,339
Kapil Dhingra 13,966,232 22,503,924 8,220,339

Proposal No. 2

The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. The results of the stockholders' vote with respect to such ratification were as follows:

FOR AGAINST ABSTAIN BROKER
NON-
VOTES
44,421,545 117,976 150,974 0
Black Diamond Therapeutics Inc. published this content on June 29, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 29, 2026 at 20:21 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]